Genetic variation in DTNBP1 influences general cognitive ability

Department of Psychiatry Research, The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Albert Einstein College of Medicine, Glen Oaks, NY 11004, USA.
Human Molecular Genetics (Impact Factor: 6.39). 06/2006; 15(10):1563-8. DOI: 10.1093/hmg/ddi481
Source: PubMed


Human intelligence is a trait that is known to be significantly influenced by genetic factors, and recent linkage data provide positional evidence to suggest that a region on chromosome 6p, previously associated with schizophrenia, may be linked to variation in intelligence. The gene for dysbindin-1 (DTNBP1) is located at 6p and has also been implicated in schizophrenia, a neuropsychiatric disorder characterized by cognitive dysfunction. We report an association between DTNBP1 genotype and general cognitive ability (g) in two independent cohorts, including 213 patients with schizophrenia or schizo-affective disorder and 126 healthy volunteers. These data suggest that DTNBP1 genetic variation influences human intelligence.


Available from: Raju Kucherlapati
  • Source
    • "Dysbindin has been implicated in cognitive performance in healthy (Luciano et al., 2009) and schizophrenia cases (Burdick et al., 2006; Fallgatter et al., 2006). Genetic variants of DTNBP1 have been associated with working memory (Donohoe et al., 2007), IQ (Zinkstok et al., 2007; Fatjovilas et al., 2011) and execution function (Luciano et al., 2009; Fatjovilas et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dystrobrevin binding protein 1 (DTNBP1) gene is pivotal in regulating the glutamatergic system. Genetic variants of the DTNBP1 affect cognition and thus may be particularly relevant to schizophrenia. We therefore evaluated the association of six single nucleotide polymorphisms (SNPs) with schizophrenia in a Malaysian population (171 cases; 171 controls). Associations between these six SNPs and schizophrenia were tested in two stages. Association signals with p < 0.05 and minor allele frequency > 0.05 in stage 1 were followed by genotyping the SNPs in a replication phase (stage 2). Genotyping was performed with sequenced specific primer (PCR-SSP) and restriction fragment length polymorphism (PCR-RFLP). In our sample, we found significant associations between rs2619522 (allele p = 0.002, OR = 1.902, 95%CI = 1.266 - 2.859; genotype p = 0.002) and rs2619528 (allele p = 0.008, OR = 1.606, 95%CI = 1.130 - 2.281; genotype p = 6.18 × 10−5) and schizophrenia. Given that these two SNPs may be associated with the pathophysiology of schizophrenia, further studies on the other DTNBP1 variants are warranted.
    Genetics and Molecular Biology 05/2015; 38(2):138-146. DOI:10.1590/S1415-4757382220140142 · 1.20 Impact Factor
  • Source
    • "Recent studies have made significant progress in identifying genes correlated with greater intelligence. (see, e.g., [41–44]) Based on such findings parents may, in the near future, be able to use genetic manipulation to improve people’s cognitive capacities—which, given the above arguments, would lead to enhancement of autonomy. Of course, genetic manipulation is not the only way to enhance autonomy; other biomedical interventions such as pharmaceuticals, or more traditional means such as education, could have the effect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some have objected to human enhancement on the grounds that it violates the autonomy of the enhanced. These objections, however, overlook the interesting possibility that autonomy itself could be enhanced. How, exactly, to enhance autonomy is a difficult problem due to the numerous and diverse accounts of autonomy in the literature. Existing accounts of autonomy enhancement rely on narrow and controversial conceptions of autonomy. However, we identify one feature of autonomy common to many mainstream accounts: reasoning ability. Autonomy can then be enhanced by improving people’s reasoning ability, in particular through cognitive enhancement; given how valuable autonomy is usually taken to be, this gives us extra reason to pursue such cognitive enhancements. Moreover, autonomy-based objections will be especially weak against such enhancements. As we will argue, those who are worried that enhancements will inhibit people’s autonomy should actually embrace those enhancements that will improve autonomy.
    Neuroethics 08/2014; 7(2). DOI:10.1007/s12152-013-9189-5 · 1.31 Impact Factor
  • Source
    • "Genetic variations in the DTNBP1 gene have been associated with alterations in human behavior and especially in cognitive abilities (Burdick et al., 2006; Fallgatter et al., 2006; Hashimoto et al., 2009; Luciano et al., 2009; Markov et al., 2009; Thimm et al., 2010; Wolf et al., 2011). In particular, single-nucleotide polymorphisms (SNPs) in the DTNBP1 gene in schizophrenia have been associated with (i) greater decline in general cognitive ability from a premorbid to a clinical state (Burdick et al., 2007), (ii) lower general cognitive ability (Burdick et al., 2006), (iii) lower scores on verbal performance and full-scale IQ tests (Zinkstok et al., 2007), and (iv) deficits on a spatial working memory task and on a go–no-go attentional response task (Donohoe et al., 2007). Moreover, patients with schizophrenia carrying a high-risk DTNBP1 haplotype are more likely to display high levels of negative symptoms (Fanous et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutant mice play an increasingly important role in understanding disease processes at multiple levels. In particular, they illuminate the impact of risk genes for disease on such processes. This article reviews recent advances in the application of mutant mice to study the intricacies of dopaminergic (DAergic) function in relation to the putative pathophysiology of psychotic illness, particularly schizophrenia, and antipsychotic drug action. It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis). In overview, it considers new schemas for understanding psychotic illness that integrate DAergic pathophysiology with developmental, social, and cognitive processes, and how mutant mouse models can reflect and inform on such schemas.
    Progress in brain research 06/2014; 211:79-112. DOI:10.1016/B978-0-444-63425-2.00004-0 · 2.83 Impact Factor
Show more